131I-Tositumomab (BexxarA®) vs. 90Y-Ibritumomab (ZevalinA®) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma

The American Cancer Society estimated 66,120 new cases of non-Hodgkin lymphoma (NHL) in the USA in 2008. Radioimmunotherapy has been shown in clinical trials to be an effective treatment for refractory/relapsed NHL. The available agents are BexxarA (R), a I-131 radiolabeled murine monoclonal antibody and ZevalinA (R), a Y-90 radiolabeled murine antibody. Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with BexxarA (R) and ZevalinA (R) in the management of low-grade refractory or relapsed NHL. This is a retrospective study (Jan 2000-Jul 2006) of 67 patients with NHL, who were treated with BexxarA (R) (31 patients, group A) or ZevalinA (R) (36 patients, group B) for refractory/relapsed disease. Group A included 16 men and 15 women, 35-81 years old (average, 59.3 A +/- 13.4). Group B included 27 men and nine women, 36-85 years old (average, 55.4 A +/- 13.8). Therapeutic doses ranged 40-138 mCi (average, 78.1 A +/- 28.2) for BexxarA (R) and 17-34 mCi (average, 28.8 A +/- 4.37) for ZevalinA (R). Objective responses were induced in 22 of the 31 patients (70.9%) in group A and 28 of the 36 patients (77.8%) in group B. Complete response was noted in 11 patients (35.5%), partial response in seven patients (22.6%), and mixed response in four patients (12.9%) in group A. There were five patients (16.1%) with stable disease and four patients (12.9%) with disease progression in the same group. Complete response was noted in 15 patients (41.7%), partial response in nine patients (25%), and mixed response in four patients (11.1%) in group B. There were four patients (11.1%) with stable disease and another four patients (11.1%) with disease progression in the same group. The average decreases at posttherapy nadir were 36.9% +/- 0.33 (group A) and 52.6% +/- 0.32 (group B) for platelets, 27.8% +/- 0.27 (group A) and 34.2% +/- 0.38 (group B) for leukocytes, and 4.9% +/- 0.15 (group A) and 7.6% +/- 0.11 (group B) for hemoglobin. Grades 3 and 4 hematological toxicity occurred in 14 patients (45.2%) treated with BexxarA (R) and 22 patients (61.1%) treated with ZevalinA (R), but was reversible. Our study suggests that clinical practice of BexxarA (R) and ZevalinA (R) radioimmunotherapy is an effective and safe adjunctive treatment for patients with NHL refractory/relapsed to conventional treatment. However, due to the small number of subjects, it was not possible to determine whether differences in the outcomes or toxicities from the two agents were statistically significant.